by Clinical Neuropsychologist Online | Wednesday, March 6, 2024 | Dementia
Abstract INTRODUCTION Tau phosphorylated at threonine-217 (pT217-tau) is a novel fluid-based biomarker that predicts onset of Alzheimer’s disease (AD) symptoms, but little is known about how pT217-tau arises in the brain, as soluble pT217-tau is dephosphorylated...
by Clinical Neuropsychologist Online | Wednesday, March 6, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 643-668, May 2024. IntroductionHealth research that focuses on Indigenous Peoples must ensure that the community in question is actively engaged, and that the results have context relevance for Indigenous Peoples. Context relevance...
by Clinical Neuropsychologist Online | Tuesday, March 5, 2024 | Dementia
Abstract INTRODUCTION Magnetic resonance imaging (MRI) biomarkers are needed for indexing early biological stages of Alzheimer’s disease (AD), such as plasma amyloid-β (Aβ42/40) positivity in Aβ positron emission tomography (PET) negative individuals. METHODS...
by Clinical Neuropsychologist Online | Tuesday, March 5, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 567-583, May 2024. Background. The diagnosis of young-onset dementia presents significant challenges both for the person and their families, which often differ from the challenges faced with late-onset dementia. Evidence of the...
by Clinical Neuropsychologist Online | Saturday, March 2, 2024 | Dementia
Dementia, Volume 23, Issue 4, Page 550-566, May 2024. BackgroundPeople with dementia and unpaid carers need to go through a social care or carers needs assessment to access and receive subsidised or fully-funded social care. With no previous evidence, this qualitative...
by Clinical Neuropsychologist Online | Friday, March 1, 2024 | Dementia
Abstract BACKGROUND Subjective cognitive impairment (SCI) measures in population-based surveys offer potential for dementia surveillance, yet their validation against established dementia measures is lacking. METHODS We assessed agreement between SCI and a validated...